Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis | Prof Jean-Jacques Kiladjian at Annual Meeting 2015

Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis | Prof Jean-Jacques Kiladjian at Annual Meeting 2015

User Photo
EMJ

5 years
703 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses the results of the phase 3 PERSIST-1 trial of the selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3, pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay